Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Yondelis Articles

Spain's Zeltia is turning a corner, say Edison analysts

28 February 2013

Zeltia's Yondelis approved for sale in 10 new countries

4 December 2012

Johnson & Johnson unit voluntarily withdraws NDA for trabectedin

3 May 2011

UK NICE gives final yes for Amgen’s Nplate but no for PharmaMar’s Yondelis

27 April 2011

UK’s NICE turns down Zeltia’s Yondelis on lack of evidence for ovarian cancer drug

14 March 2011

Spain’s Zeltia posts 74% rise in EBITDA, with Yondelis sales up 65% in 2010

28 February 2011

UK’s NICE turns down PharmaMar’s Yondelis and GlaxoSmithKline’s Arzerra

20 September 2010

PharmaMar/Centocor’s Yondelis gets five new approvals outside the European Economic Area

17 March 2010

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS